Healthcare Companies Report Results, Patents, and Stock Movements - Analyst Notes on Puma Biotechnology, Alnylam, INSYS Therapeutics, Peregrine Pharmaceuticals, and VIVUS

NEW YORK, April 10, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Puma Biotechnology, Inc. (NYSE: PBYI), Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), INSYS Therapeutics, Inc. (NASDAQ: INSY), Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), and VIVUS Inc (NYSE: ESC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

--

Puma Biotechnology, Inc. Analyst Notes 

On April 7, 2014, Puma Biotechnology, Inc. (Puma Biotechnology) presented positive results from the Phase II clinical trial of its investigational drug PB272 (neratinib) for the neoadjuvant treatment of breast cancer (I-SPY 2 TRIAL) in an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2014 in San Diego, California. According to Puma Biotechnology, the I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2) is a collaborative effort among academic investigators from approximately 20 major cancer research centers across the country, the U.S. Food and Drug Administration, Quantum Leap Healthcare Collaborative, and the Foundation for the National Institutes of Health (FNIH) Cancer Biomarkers Consortium including major supporters such as The Safeway Foundation and the Bill Bowes Foundation. The full analyst notes on Puma Biotechnology, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04102014/PBYI/report.pdf

--

Alnylam Pharmaceuticals, Inc. Analyst Notes 

On April 7, 2014, Alnylam Pharmaceuticals, Inc. (Alnylam) announced that the European Patent Office (EPO) has upheld the McSwiggen EP 1423406 ('406) patent in oral opposition proceedings in Munich, Germany. According to the release, the McSwiggen patent estate is owned by Alnylam, and was recently obtained through the Company's acquisition of Sirna Therapeutics from Merck. Additionally, the Company stated that the McSwiggen patent family comprises a core component of Alnylam's overall intellectual property (IP) estate for the advancement of RNAi therapeutics as a new class of medicines. Commenting on the news, Laurence Reid, Ph.D., Senior Vice President and Chief Business Officer of Alnylam, stated, "We are pleased with the European Patent Office's decision to uphold the '406 patent from our McSwiggen patent family, a key component of the IP estate we recently obtained through our acquisition of Sirna Therapeutics from Merck. This patent has broad and significant claims describing chemical modifications of RNAi therapeutics, which we believe are critical for the development and commercialization of all RNAi therapeutics. Our IP estate remains a cornerstone in our efforts to advance RNAi therapeutics to patients in need." The full analyst notes on Alnylam Pharmaceuticals, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04102014/ALNY/report.pdf

--

INSYS Therapeutics, Inc. Analyst Notes 

On March 31, 2014, INSYS Therapeutics, Inc. (INSYS) announced that it has completed its previously disclosed three-for-two stock split, effected through a stock dividend. According to the release, the record date for the stock split was the close of business on March 17, 2014, and share distribution occurred on March 28, 2014. Additionally, INSYS said that consequent to the dividend, shareholders received one additional share of the Company common stock, par value $0.0002145, for each two shares they held as of the record date. INSYS President and CEO, Michael L. Babich, stated, "This action increases the liquidity of our stock, and reflects our confidence in the strength and continuing growth of our Company. We are committed to remaining profitable and continuing to build shareholder value with our marketed products and through our robust R&D pipeline." The full analyst notes on INSYS Therapeutics, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04102014/INSY/report.pdf

--

Peregrine Pharmaceuticals Inc. Analyst Notes 

On April 7, 2014, Peregrine Pharmaceuticals Inc.'s (Peregrine Pharmaceuticals) stock went up by 2.72% to $1.89 per share. For the past three-month trading period, the Company's stock went up by 19.62%, compared to the Nasdaq Composite which went down by 1.77%. The full analyst notes on Peregrine Pharmaceuticals Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04102014/PPHM/report.pdf

--

VIVUS Inc. Analyst Notes 

On April 7, 2014, VIVUS Inc.'s (VIVUS) stock went down 6.09%, at $5.09 per share. Over the past five-day trading period, VIVUS shares went down by 11.00%, compared to the Nasdaq Composite which went down by 2.83% over the same trading session. The full analyst notes on VIVUS Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04102014/ESC/report.pdf

--

About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

--

=============

EDITOR NOTES: 

• This is not company news. We are an independent source and our views do not reflect the companies mentioned.
• Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
• This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
• If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
• For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
• Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.

COMPLIANCE PROCEDURE 

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE 

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED 

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED